everolimus

Overview

Everolimus is a clinically used inhibitor of the mechanistic target of rapamycin kinase (mTOR), a central regulator of cell growth, proliferation, metabolism, and survival. As an mTOR-targeted therapy, it is used in a range of diseases in which dysregulated PI3K/AKT/mTOR signaling contributes to pathological cell growth or treatment resistance. In biomedical research, everolimus is frequently discussed alongside sirolimus as a representative mTOR inhibitor, with particular relevance to oncology, transplant-related pharmacology, and pediatric vascular abnormalities.

Pharmacologically, everolimus modulates downstream signaling from the PI3K/AKT/mTOR pathway and is often studied in combination with other therapies to enhance antitumor activity or overcome resistance. Recent publications also continue to examine its safety profile, including potential hepatotoxicity and renal effects, reflecting the need to balance therapeutic benefit with organ-specific toxicity.

Focus of Latest Publications

Recent publications have continued to examine everolimus as an mTOR-targeted therapy across oncology, transplantation, and experimental nephrotoxicity models. In a randomized phase 2 trial in biopsy-proven diffuse intrinsic pontine glioma, everolimus was tested with radiotherapy alongside erlotinib and dasatinib. Although the trial was stopped for futility because overall survival was not improved versus a historical control cohort in any arm, everolimus was associated with a median overall survival of 11.9 months and showed fewer ocular, renal, skin, and gastrointestinal adverse effects and less treatment discontinuation for toxicity. The study also reported that alterations in or activation of the mTOR pathway were associated with better response to everolimus, suggesting a potential theranostic role for pathway profiling.

Everolimus has also been explored in combination strategies for other tumors. In pancreatic neuroendocrine neoplasms, it was combined with the EZH2 inhibitor GSK126 in preclinical experiments, where the combination more effectively inhibited cell proliferation and tumor growth than GSK126 alone. The study proposed that GSK126 suppresses the PI3K/AKT/mTOR pathway to induce ferroptosis, while HMGCS1 may mediate resistance through pathway reactivation, providing a mechanistic rationale for pairing everolimus with other targeted agents in this disease. A review of next-generation meningioma therapies likewise highlighted everolimus among emerging PI3K/AKT/mTOR-directed options under investigation for biomarker-driven treatment approaches.

Outside oncology, everolimus has been evaluated in settings relevant to transplant medicine and renal injury. In a study of subtotal nephrectomized rats, low-dose tacrolimus worsened renal dysfunction, albuminuria, and interstitial fibrosis, and concomitant everolimus partially attenuated these functional and histopathological changes. Another publication focused on liver transplant recipients examined the clinical impact and cost-effectiveness of adding everolimus to calcineurin inhibitor-based regimens, specifically in relation to cancer, infection, and renal dysfunction, although the abstract provided only the study aim rather than results.

Safety-focused experimental work has also expanded understanding of everolimus toxicity. Using zebrafish models and integrated transcriptomic and metabolomic analyses, investigators found that everolimus, like sirolimus, caused hepatotoxicity even at standard concentrations, with more pronounced effects at higher doses, including reduced liver size, elevated ALT, widened hepatocyte gaps, and vacuolization. These toxic effects were linked to aberrant activation of the PI3K/AKT pathway and disrupted lipid metabolism, particularly involving downregulation of PCK1, underscoring the importance of blood concentration monitoring and dose optimization in pediatric use.

Key Publications

May Tacrolimus-accelerated renal interstitial injury in subtotal nephrectomized rats and its pharmacological modulation by everolimus. (Toxicology letters, 2026, PMID 42061595): "the effects of concomitant everolimus treatment were examined as a pharmacological modulator."
Apr Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial. (Nature medicine, 2026, PMID 42032072): "...mTOR inhibitor everolimus and multitargeted tyrosine kinase inhibitor dasatinib in combination with radiotherapy..."
Apr Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal Function. (Transplantation, 2026, PMID 42024308): "This study evaluated clinical impacts and cost-effectiveness of adding everolimus (EVR) to a calcineurin inhibitor (CNI)-based regimen in liver transplant recipients."
Apr Next-Generation Therapies for Meningioma: Overcoming Barriers and Expanding Treatment Options. (Cancer investigation, 2026, PMID 42017452): "including targeted agents against the PI3K/AKT/mTOR and Sonic Hedgehog pathways (e.g., everolimus, vismodegib)"
May HMGCS1 as a potential mediator of resistance to EZH2 inhibition via ferroptosis mediated by PI3K/AKT/mTOR pathway in the pancreatic neuroendocrine neoplasms. (Endocrine-related cancer, 2026, PMID 42013002): "Furthermore, combining GSK126 with everolimus, an mTOR inhibitor used clinically for pNENs, more effectively inhibited cell proliferation and tumor growth."
Jun Hepatotoxicity Mechanisms of Sirolimus and Everolimus Unveiled Through Metabolomics and Transcriptomics Analysis. (Journal of applied toxicology : JAT, 2026, PMID 41320894): "Sirolimus and everolimus, two representative inhibitors of the mammalian target of rapamycin (mTOR), have distinct therapeutic effects on numerous paediatric diseases that do not have specific treatments, particularly vascular abnormalities, but their safety regarding the growth and development of children is still worth considering."